Navigation Links
WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
Date:10/23/2008

Earnings Conference Call to be Held on November 13, 2008 at 8:00 am

(Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong)

SHANGHAI, China, Oct. 23 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release unaudited financial results for the third quarter 2008 after the US market close on Wednesday, November 12, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations section of its website at http://www.wuxiapptec.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Thursday, November 13, 2008 to discuss its 2008 third quarter financial results and recent business activities. The conference call may be accessed by calling:

Conference ID: 70474888

United States 866-586-2813

China, Northern Region 10-800-611-0127

China, Southern Region 10-800-361-0079

Hong Kong 800-965-808

United Kingdom 0-800-056-9662

International +61-2-8524-6650

A telephone replay will be available two hours after the call's completion until December 14, 2008 at (US) +1-866-214-5335/ (HK) 800-901-596 / (China) 10-800-140-0386 / (UK) 0-800-731-7846 / (International) +61-2-8235-5000. Passcode: 70474888.

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

For further information, please contact:

WuXi PharmaTech (Cayman) Inc.

Dr. Hai Mi

Executive Director of Investor Relations and Business Planning

Tel: +86-21-5046-3726

Email: ir@wuxiapptec.com

Burns McClellan

Juliane Snowden

Vice President of Investor Relations

Tel: +1-212-213-0006

Email: jsnowden@burnsmc.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
2. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
3. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
4. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
5. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
6. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
9. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
10. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
11. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)...  The global market for clinical laboratory services ... new report from Kalorama Information.  In addition to ... evaluate disease progression, monitor drug treatment and conditions, ... healthcare market research firm,s report, Clinical ... of the medical laboratory industry and the trends ...
(Date:3/27/2017)... 27, 2017 The new research portal ... library of reports on Valero Energy , offering extensive ... petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest ... go green. Ethanol today, even though touted as a green ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led by ... in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The article ... coronary artery disease (CAD). Lam is an assistant professor at the Department of ...
(Date:3/27/2017)... , March 27, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... coverage option for U.S. consumers who want to have ... DarioHealth has signed strategic alliance agreements with partners across ... coverage benefits, and if approved, will supply and bill ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/16/2017)... 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... Used combined in one project, ... ...
(Date:3/7/2017)... LAKE CITY , March 7, 2017   ... that help top global companies identify the best talent, ... as Chief Sales Officer (CSO) and Diana ... Kucer,s appointments round out a seasoned executive team poised to ... and beyond, building on a year of record bookings ...
Breaking Biology News(10 mins):